Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer

Withdrawn before enrolling

Conditions studied: Head and Neck Squamous Cell Carcinoma

In brief

This study will investigate the clinical validity and clinical utility of the OncoPrism-HNSCC (Head and Neck Squamous Cell Carcinoma) test.

Key facts

Study ID

NCT05296135

Run by

Cofactor Genomics, Inc.

People needed

0

Starts

2020-02-05

Expected to finish

2025-02-20

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must have been diagnosed with recurrent or metastatic HNSCC.
• Subject must have received, or be scheduled to receive, at least one dose of FDA approved anti-PD-1/PD-L1 immunotherapy for treatment of their cancer.
• Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1/PD-L1 immunotherapy.
• Subject must have a RECIST determination of PD-L1/PD-1 inhibitor-treatment by imaging or clinical assessment.
• Willing to provide electronic informed consent per IRB-approved protocol.
• Able to speak, read, and comprehend English or Spanish fluently.
• Subject is 18 years of age or older.
• Subjects must have sufficient tissue available to fulfill the specimen requirements of the study, as defined in the Specimens to be Collected section of protocol.

You may not qualify if…

• Subject shall not have received immunotherapy in combination with other therapy modality such as radiation therapy, platinum-based chemotherapy, or a taxane.
• Subject shall not have received immunotherapy outside of FDA approved use as of the date of this protocol.
• Subject shall not have inability or unwillingness to provide informed consent.
• Subject shall not have other cancers than listed above (other histologies).
• Subject shall not have already participated in this trial.
• Subject specimens shall not have <10% tumor cellularity measured by H\&E.
• More than 24 months shall not have transpired between biopsy harvest and studied immunotherapy treatment.

Where it is running

• Curebase — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.